Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation.
Animals
Cell Line, Tumor
Cellular Reprogramming
Energy Metabolism
/ genetics
Glycine
Humans
Mice
Mutation
Neoplasm Proteins
/ genetics
Neoplasms
/ diet therapy
Phosphoglycerate Dehydrogenase
/ genetics
Phosphoproteins
/ genetics
Proteome
/ genetics
RNA Splicing Factors
/ genetics
Serine
Transcriptome
Xenograft Model Antitumor Assays
Amino acid metabolism
Cancer
Metabolism
Oncology
Journal
The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877
Informations de publication
Date de publication:
08 08 2019
08 08 2019
Historique:
entrez:
9
8
2019
pubmed:
9
8
2019
medline:
17
6
2020
Statut:
epublish
Résumé
Cancer-associated mutations in the spliceosome gene SF3B1 create a neomorphic protein that produces aberrant mRNA splicing in hundreds of genes, but the ensuing biologic and therapeutic consequences of this missplicing are not well understood. Here we have provided evidence that aberrant splicing by mutant SF3B1 altered the transcriptome, proteome, and metabolome of human cells, leading to missplicing-associated downregulation of metabolic genes, decreased mitochondrial respiration, and suppression of the serine synthesis pathway. We also found that mutant SF3B1 induces vulnerability to deprivation of the nonessential amino acid serine, which was mediated by missplicing-associated downregulation of the serine synthesis pathway enzyme PHGDH. This vulnerability was manifest both in vitro and in vivo, as dietary restriction of serine and glycine in mice was able to inhibit the growth of SF3B1MUT xenografts. These findings describe a role for SF3B1 mutations in altered energy metabolism, and they offer a new therapeutic strategy against SF3B1MUT cancers.
Identifiants
pubmed: 31393856
pii: 125022
doi: 10.1172/JCI125022
pmc: PMC6819102
doi:
pii:
Substances chimiques
Neoplasm Proteins
0
Phosphoproteins
0
Proteome
0
RNA Splicing Factors
0
SF3B1 protein, human
0
Serine
452VLY9402
Phosphoglycerate Dehydrogenase
EC 1.1.1.95
Glycine
TE7660XO1C
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
4708-4723Subventions
Organisme : NCI NIH HHS
ID : R01 CA194024
Pays : United States
Organisme : NCI NIH HHS
ID : K12 CA090625
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA214494
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008752
Pays : United States
Organisme : NHLBI NIH HHS
ID : K08 HL136894
Pays : United States
Références
Nature. 2012 May 16;486(7403):400-4
pubmed: 22722201
Nature. 2013 Jan 24;493(7433):542-6
pubmed: 23242140
Nat Cell Biol. 2015 Oct;17(10):1317-26
pubmed: 26302408
J Biol Chem. 2015 Jan 2;290(1):457-66
pubmed: 25404730
Cell Metab. 2019 Jun 4;29(6):1410-1421.e4
pubmed: 30905671
Cell Metab. 2016 Jan 12;23(1):27-47
pubmed: 26771115
Nat Commun. 2016 Feb 04;7:10615
pubmed: 26842708
JAMA Oncol. 2017 Jan 1;3(1):58-66
pubmed: 27584578
N Engl J Med. 2011 Dec 29;365(26):2497-506
pubmed: 22150006
Oncogene. 2002 Nov 7;21(51):7897-900
pubmed: 12420227
Ann Oncol. 2018 Aug 1;29(8):1727-1740
pubmed: 29945232
Nat Commun. 2016 May 10;7:11479
pubmed: 27161491
Nat Chem Biol. 2016 Jun;12(6):452-8
pubmed: 27110680
N Engl J Med. 2011 Oct 13;365(15):1384-95
pubmed: 21995386
Cancer Res. 2015 May 15;75(10):1949-58
pubmed: 25788694
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Cell. 2015 Jul 30;162(3):540-51
pubmed: 26232224
Cancer Res. 2014 Dec 15;74(24):7521-33
pubmed: 25377470
Nat Cell Biol. 2018 Jul;20(7):775-781
pubmed: 29941933
Sci Rep. 2017 Apr 10;7:46079
pubmed: 28393905
Nat Genet. 2016 Jun;48(6):607-16
pubmed: 27158780
Breast Cancer Res Treat. 2011 Jan;125(2):421-30
pubmed: 20352489
Nat Commun. 2014 Sep 23;5:4961
pubmed: 25247763
Cell Rep. 2015 Nov 3;13(5):1033-45
pubmed: 26565915
Nature. 2012 Nov 15;491(7424):458-462
pubmed: 23064226
Nat Genet. 2013 Feb;45(2):133-5
pubmed: 23313955
Nat Genet. 2011 Jul 31;43(9):869-74
pubmed: 21804546
Oncotarget. 2016 Jan 12;7(2):1765-76
pubmed: 26625201
Cancer Res. 2013 Jun 1;73(11):3248-61
pubmed: 23580570
Blood. 2019 Jul 11;134(2):186-198
pubmed: 31010849
Clin Chem. 2017 Aug;63(8):1370-1376
pubmed: 28615231
Cell Metab. 2018 Oct 2;28(4):573-587.e13
pubmed: 30017355
Nature. 2018 Oct;562(7728):526-531
pubmed: 30333627
Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6205-14
pubmed: 26508629
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2835-40
pubmed: 19196980
Cell Rep. 2018 Mar 27;22(13):3507-3520
pubmed: 29590619
Nature. 2011 Sep 11;478(7367):64-9
pubmed: 21909114
Cell Rep. 2018 Aug 28;24(9):2381-2391.e5
pubmed: 30157431
Oncotarget. 2016 Nov 29;7(48):79722-79735
pubmed: 27806325
Nature. 2017 Apr 19;544(7650):372-376
pubmed: 28425994
Science. 2015 May 8;348(6235):666-9
pubmed: 25954003
Blood. 2016 Oct 13;128(15):1913-1917
pubmed: 27488349
Nat Genet. 2018 May;50(5):645-651
pubmed: 29610475
PLoS Genet. 2013;9(12):e1004034
pubmed: 24385928
PLoS Comput Biol. 2015 Mar 13;11(3):e1004105
pubmed: 25768983
Sci Transl Med. 2016 May 11;8(338):338ra67
pubmed: 27169803
Cancer Cell. 2016 Nov 14;30(5):750-763
pubmed: 27818134
Oncotarget. 2017 Dec 5;8(70):115018-115027
pubmed: 29383138
Nat Cell Biol. 2018 Jul;20(7):782-788
pubmed: 29941931
Nature. 2012 Nov 15;491(7424):399-405
pubmed: 23103869
Trends Biochem Sci. 2017 Feb;42(2):98-110
pubmed: 27712956
Nature. 2011 Aug 18;476(7360):346-50
pubmed: 21760589
Nucleic Acids Res. 2017 Jan 4;45(D1):D331-D338
pubmed: 27899567
Cell. 2015 Jul 30;162(3):552-63
pubmed: 26232225
Cell Rep. 2017 Jul 18;20(3):721-736
pubmed: 28723573
J Pathol. 2015 Mar;235(4):571-80
pubmed: 25424858
Hum Mol Genet. 2014 Dec 1;23(23):6356-65
pubmed: 25008109
Leukemia. 2015 May;29(5):1092-103
pubmed: 25428262